Alnylam Pharmaceuticals is a biotechnology company that focuses on RNA interference (RNAi) therapeutics. The company's products are designed to silence specific genes that cause diseases. Alnylam's pipeline includes products for the treatment of genetic, cardio-metabolic, and hepatic infectious diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.